# Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

Study · id `cardio:ct-nct01192724` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01192724](<https://clinicaltrials.gov/study/NCT01192724>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01192724

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 630 participants.

## Technical summary

Registry record NCT01192724. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 630 participants (enrolled count; ClinicalTrials.gov record NCT01192724, source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01192724, source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01192724, source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01192724, source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01192724, source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01192724-2016-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
- Acronym: ABCD
- Condition: Coronary Artery Disease
- Intervention (Drug): Cilostazol
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease (`cardio:pubmed-24439986`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9fc460e6a925b77eb0722f70638a7c2c3eef47816ca34cff339f6f0bb1281ae8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
